GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » MedAvail Holdings Inc (OTCPK:MDVLQ) » Definitions » Cash Conversion Cycle

MedAvail Holdings (MedAvail Holdings) Cash Conversion Cycle : 3,487.53 (As of Jun. 2023)


View and export this data going back to 2020. Start your Free Trial

What is MedAvail Holdings Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

MedAvail Holdings's Days Sales Outstanding for the three months ended in Jun. 2023 was 56.21.
MedAvail Holdings's Days Inventory for the three months ended in Jun. 2023 was 3771.8.
MedAvail Holdings's Days Payable for the three months ended in Jun. 2023 was 340.48.
Therefore, MedAvail Holdings's Cash Conversion Cycle (CCC) for the three months ended in Jun. 2023 was 3,487.53.


MedAvail Holdings Cash Conversion Cycle Historical Data

The historical data trend for MedAvail Holdings's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedAvail Holdings Cash Conversion Cycle Chart

MedAvail Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Cash Conversion Cycle
634.25 106.27 43.29 44.57

MedAvail Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 995.10 49.31 56.37 1,819.91 3,487.53

Competitive Comparison of MedAvail Holdings's Cash Conversion Cycle

For the Pharmaceutical Retailers subindustry, MedAvail Holdings's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedAvail Holdings's Cash Conversion Cycle Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedAvail Holdings's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where MedAvail Holdings's Cash Conversion Cycle falls into.



MedAvail Holdings Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

MedAvail Holdings's Cash Conversion Cycle for the fiscal year that ended in Dec. 2022 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=14.39+48.88-18.7
=44.57

MedAvail Holdings's Cash Conversion Cycle for the quarter that ended in Jun. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=56.21+3771.8-340.48
=3,487.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedAvail Holdings  (OTCPK:MDVLQ) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


MedAvail Holdings Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of MedAvail Holdings's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


MedAvail Holdings (MedAvail Holdings) Business Description

Traded in Other Exchanges
N/A
Address
4720 East Cotton Gin Loop, Suite 220, Phoenix, AZ, USA, 85040
MedAvail Holdings Inc is a telehealth-enabled pharmacy technology company. It operates in two segments: Retail Pharmacy Services and Pharmacy Technology. It generates the majority of revenue from the Retail Pharmacy Services segment, which is into operating SpotRx, a full-service retail pharmacy utilizing MedAvail's automated pharmacy technology, primarily servicing Medicare patients in the United States. The Pharmacy Technology segment develops and commercializes the MedCenter for direct sale or lease to third-party customers.
Executives
Ramona Seabaugh officer: Chief Financial Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Michael R Kramer director 3910 BRICKWAY BLVD, SANTA ROSA CA 95403
Paul D Johnson director 440 N BARRANCA AVE #3550, COVINA CA 91723
Glen D. Stettin director C/O EXPRESS SCRIPTS HOLDING COMPANY, ONE EXPRESS WAY, ST. LOUIS MO 63121
Mark Edward Doerr director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Abg Wtt-medavail Ltd 10 percent owner 15 QUEENS ROAD CENTRAL, UNIT 3002-3004, 30TH FLOOR, GLOUCESTER TWR, THE LANDMARK, HONG KONG F4 0000000000
Redco Ii Master Fund, L.p. director, 10 percent owner ONE LETTERMAN DRIVE, BLDG D, STE D3-300, SAN FRANCISCO CA 94129
Alyeska Fund Gp, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investments, Llc 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Anand Parekh 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Master Fund, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Alyeska Investment Group, L.p. 10 percent owner 77 WEST WACKER DRIVE, 7TH FLOOR, CHICAGO IL 60601
Steven Hess officer: Executive Vice President C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4
Edwin Kilroy director, officer: Chief Executive Officer C/O MEDAVAIL TECHNOLOGIES INC., 6665 MILLCREEK DR, UNIT 1, MISSISSAUGA A6 L5N 5M4

MedAvail Holdings (MedAvail Holdings) Headlines